ClinicalTrials.gg
CompletedNCT04930094GCAptAINUpdated Mar 31, 2026

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

A Phase 3 interventional study of Secukinumab 300 mg and Placebo in Giant Cell Arteritis (GCA), sponsored by Novartis Pharmaceuticals. Completed at 104 sites in 27 countries. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Giant Cell Arteritis with a site in Spain — none open to participants now, none under way, none of them phase 3. Giant Cell Arteritis · Spain.

Started
2021
with 1 other
Phase 3
6 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Novartis Pharmaceuticals

Among the 11 studies in Giant Cell Arteritis with a site in Spain, this one is one of 2 that started in 2021, is one of 6 in phase 3, and was the 10th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

None of the 11 studies in Giant Cell Arteritis with a site in Spain is open now. The open studies under Giant Cell Arteritis, anywhere →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Giant Cell Arteritis with a site in Spain as a file.
02

Study summary

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)

Read the detailed description

Randomized, parallel-group, double-blind, placebo-controlled, multi-center, Phase III study to evaluate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)

03

Conditions studied

  • Giant Cell Arteritis (GCA)

Keywords

  • GCA
  • temporal arteritis
  • giant cell arteritis
  • vasculitis
  • secukinumab
  • monoclonal antibody
  • AIN457
  • prednisone taper regimen
  • glucocorticoid
  • GC
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study.
  3. Male or non-pregnant, non-lactating female patients at least 50 years of age.
  4. Diagnosis of GCA based on meeting all of the following criteria:

    • Age at onset of disease ≥ 50 years.
    • Unequivocal cranial symptoms of GCA (e.g., new-onset localized headache, scalp or temporal artery tenderness, permanent or temporary ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon mastication), and/or unequivocal symptoms of polymyalgia rheumatica (PMR) (defined as shoulder and/or hip girdle pain associated with inflammatory morning stiffness) and/or symptoms of limb ischemia (claudication).
    • TAB revealing features of GCA and/or cross-sectional imaging study such as ultrasound (e.g., cranial or axillary), MRI/MRA, CTA, or PET-CT with evidence of vasculitis.
  5. Active disease as defined by meeting both of the following within 6 weeks of BSL (see Section 8.1 for details)

    • Presence of signs or symptoms attributed to active GCA and not related to prior damage (e.g., visual loss that occurred prior to 6 weeks before BSL without new findings occurring within 6 weeks of BSL)
    • Elevated ESR ≥ 30 mm/hr or CRP ≥ 10 mg/L attributed to active GCA or active GCA on TAB or on imaging study.
  6. Patients to meet definition of new-onset GCA or relapsing GCA:

    • Definition of new-onset GCA*: GCA that is diagnosed within 6 weeks of BSL visit
    • Definition relapsing GCA: GCA diagnosed > 6 weeks before BSL visit and following institution of an appropriate treatment course for GCA, participant has experienced recurrence of active symptoms or signs of disease after resolution.

      • The 6-week timeframe is to be calculated from the date of suspected GCA diagnosis. Suspected diagnosis is defined as date when GC therapy was initiated.
  7. Patients' current GCA episode should be treatable with a dose of prednisone (or equivalent) designed to adequately achieve disease control in accordance with international guidelines. If this is not possible due to concerns regarding GC toxicity, the patient should not be enrolled. It must be medically appropriate for the patient to receive prednisone (or equivalent) 20 mg-60 mg daily (or equivalent) at BSL.
  8. Patients taking MTX (≤ 25 mg/week) are allowed to continue their medication provided they have taken it for at least 2 months and are on a stable dose for at least 4 weeks prior to randomization and if they are on stable folic acid treatment before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
  2. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during study treatment or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 weeks after treatment discontinuation). Also, contraception should be used in accordance with locally approved prescribing information of concomitant medications administered (e.g., Rescue Treatment). Effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Bilateral oophorectomy with or without hysterectomy, total hysterectomy or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment are they not considered to be of child-bearing potential.
    • Bilateral tubal occlusion, Bilateral tubal ligation (at least six weeks before taking study treatment.
    • Male sterilization (vasectomy) of male partner(s) of the female participant at least 6 months prior to screening.
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). NOTE: for United Kingdom: with spermicidal foam/gel/film/cream/vaginal suppository.
    • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example, hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS). In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
    • Women are considered if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women participants are considered not of child-bearing potential if they are post-menopausal or have had, surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks prior to first dose of study treatment in the study . In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered to be not of child-bearing potential.

    If local regulations are more stringent than the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Form (ICF).

  3. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor.
  4. Patients treated with any cell-depleting therapies.
  5. Previous participation in a clinical trial where the outcome of treatment with the GCA drug is unknown. This does not include trials where the treatment for GCA was GCs, MTX, leflunomide or azathioprine
  6. Patients who have been treated with inhibitors directly targeting IL-1, or IL-1 receptor, IL-12 and IL-23, or abatacept within 4 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL.
  7. Treatment with tocilizumab, other IL-6/IL6-R inhibitor or JAK inhibitor within 12 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL, or if the patient did not respond to or experienced a relapse during treatment any time before BSL.
  8. Any treatment received for GCA in which patient did not respond to treatment or experienced a relapse while on that treatment any time before BSL. This also includes patients who were treated in a clinical trial for GCA. Patients who failed on treatment with GCs, MTX, leflunomide and/or azathioprine may be included.
  9. Patients treated with i.v. immunoglobulins or plasmapheresis within 8 weeks prior to BSL.
  10. Patients treated (i.e. systemic therapy) with cyclophosphamide or hydroxychloroquine within 6 months prior to BSL, or tacrolimus, everolimus, cyclosporine A, azathioprine, sulfasalazine, mycophenolate mofetil within 4 weeks prior to BSL.
  11. Patients treated with leflunomide within 8 weeks of BSL unless a cholestyramine washout has been performed in which case the patient must be treated within 4 weeks of BSL.
  12. Patients treated with an alkylating agent within 5 years prior to BSL, unless specified in other exclusion criteria.
  13. Patients requiring or anticipated to require systemic chronic therapy or pulses of glucocorticoids for reasons other than GCA (e.g., , asthma, planned surgery) at screening or randomization.
  14. Criterion removed in protocol V01.
  15. Patients requiring chronic (i.e., not occasional "prn") high potency opioid analgesics for pain management.
  16. Use of other drugs within 5 half-lives of enrollment or within 30 days (e.g. small molecules) or until the expected pharmacodynamic effect has returned to BSL (e.g., biologics), whichever is longer; or longer if required by local regulations.
  17. History of or to any of the study treatments or its or to drugs of similar chemical classes.
  18. Active IBD or other ongoing inflammatory diseases other than GCA that might confound the evaluation of the benefit of secukinumab therapy, including uveitis at screening or randomization.
  19. Major ischemic event (e.g., myocardial infarction, stroke, etc.) or (TIA) (except ischemia-related vision loss), related or unrelated to GCA, within 12 weeks of screening.
  20. Confirmed diagnosis of any primary form of systemic vasculitis, other than GCA.
  21. Any other systemic biologics (e.g., denosumab, TNFα inhibitors) within 4 weeks or within 5 half-lives of the drug (whichever is longer) prior to BSL, or anticipated use of a systemic biologic prior to EOS
  22. Active ongoing diseases which in the opinion of the investigator immunocompromises the patient and/or places the patient at unacceptable risk for treatment with immunomodulatory therapy.
  23. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension (≥ 160/95 mmHg), congestive heart failure ( (NYHA) status of class III or IV) and uncontrolled diabetes mellitus.
  24. History of liver disease or liver injury as indicated by abnormal liver function tests (LFTs) such as (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or serum . The investigator should be guided by the following criteria:

    • SGOT (AST) and SGPT (ALT) may not exceed 3 × the (ULN). A single parameter elevated up to and including 3 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
    • Alkaline phosphatase may not exceed 2 × ULN. An elevation up to and including 2 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
    • Total bilirubin may not exceed 2 × ULN. If the total bilirubin concentration is increased above 2 × ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin.
  25. Criterion removed in protocol V01
  26. Screening total WBC count \< 3,000/μL, or \< 100,000/μL or neutrophils \< 1,500/μL or \< 8.3 g/dL (83 g/L).
  27. Active infections during the last 2 weeks prior to randomization.
  28. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold Plus test. Patients with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB. If the test result is indeterminate, the investigator may repeat the test once or may proceed directly to perform the work-up for TB as per local procedures. If presence of latent TB is established then treatment according to local country guidelines must be initiated prior to randomization.
  29. Known infection with (HIV), , or (if not treated and cured) at screening or randomization
  30. History of lymphoproliferative disease or any known or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  31. (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster vaccines) within 6 weeks prior to BSL, or planned or anticipated potential need for live vaccination during study participation until 12 weeks after last study treatment administration.
  32. Current severe progressive or uncontrolled disease, which in the judgment of the clinical investigator renders the patient unsuitable for the trial.
  33. Any medical or psychiatric condition, which, in the investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol.
  34. Donation or loss of 400 mL or more of blood within 8 weeks before randomization.
  35. History or evidence of ongoing alcohol or drug abuse, within the last 6 months before randomization.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Secukinumab 300 mg

    Secukinumab 300 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.

    Biological: Secukinumab 300 mg

  • Placebo comparator
    Placebo

    Placebo to secukinumab s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Placebo will be given in combination with a specified 52-week prednisone taper regimen.

    Other: Placebo

  • Experimental
    Secukinumab 150 mg

    Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.

    Biological: Secukinumab 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with sustained remission

    Primary objective is to determine whether the efficacy of secukinumab 300 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week glucocorticoids (GC) taper regimen in participants with giant cell arteritis (GCA) based on sustained remission at Week 52

    Time frame: 52 weeks

Secondary outcomes

  1. Cumulative GC Dose

    To demonstrate that the efficacy of secukinumab 300 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen, in participants with GCA, based on cumulative GC dose through Week 52

    Time frame: 52 weeks

  2. Proportion of participants with sustained remission

    To demonstrate that the efficacy of secukinumab 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen in participants with GCA based on sustained remission at Week 52

    Time frame: 52 weeks

  3. Cumulative GC Dose

    To demonstrate that the efficacy of secukinumab 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen, in participants with GCA, based on cumulative GC dose through Week 52

    Time frame: 52 Weeks

  4. Time to first use of Escape or Rescue Treatment due to GCA as measured in days

    To demonstrate that the efficacy of secukinumab 300 mg s.c. or 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen in participants with GCA based on time to first use of Escape Treatment or Rescue Treatment due to GCA

    Time frame: 52 weeks

  5. Change in SF-36 score (PCS)

    To demonstrate that the effect on participant's QoL of secukinumab 300 mg s.c. or 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen, in participants with GCA based on change of SF-36 score (PCS) at Week 52

    Time frame: 52 weeks

  6. Glucocorticoid Toxicity Index (GTI) as measured by the Aggregate Improvement Score (AIS)

    To demonstrate that the effect of secukinumab 300 mg s.c. or 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen, in participants with GCA based on Glucocorticoid Toxicity Index (GTI)

    Time frame: 52 weeks

  7. Change in FACIT-Fatigue Score

    To demonstrate that the effect on participant's QoL of secukinumab 300 mg s.c. or 150 mg s.c. in combination with a 26-week GC taper regimen is superior to placebo in combination with a 52-week GC taper regimen, in participants with GCA based on change in FACIT-Fatigue score at Week 52

    Time frame: 52 weeks

  8. Number of participants with Adverse events (AEs) and Serious AEs (SAEs)

    Number of participants with AEs and SAEs as a measure of safety and tolerability

    Time frame: 52 weeks

  9. Number of participants with clinically significant changes in clinical laboratory measures and vital signs

    Number of participants with clinically significant changes in clinical laboratory measures and vital signs, as assessed by the Investigator

    Time frame: 52 weeks

07

Study locations

104 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • IRIS Research and Development
    Plantation, Florida 33324, United States
  • Sarasota Arthritis Res Ctr
    Sarasota, Florida 34239, United States
  • Novartis Investigative Site
    Iowa City, Iowa 52242, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • Osteoporosis and Clinical Trial Ctr
    Hagerstown, Maryland 21740, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Precision Comp Clin Research
    Grapevine, Texas 76051, United States
  • Advanced Rheumatology of Houston
    Spring, Texas 77382, United States
  • Novartis Investigative Site
    La Plata, Buenos Aires B1900AWT, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Parramatta, New South Wales 2150, Australia
  • Novartis Investigative Site
    Southport, Queensland 4215, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Heidelberg Heights, Victoria 3081, Australia
  • Novartis Investigative Site
    Malvern East, Victoria 3145, Australia
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
  • Novartis Investigative Site
    Liverpool, 2170, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Juiz de Fora, Minas Gerais 36010 570, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • Novartis Investigative Site
    Sao Jose Rio Preto, São Paulo 15090 000, Brazil
  • Novartis Investigative Site
    Plovdiv, 4000, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Novartis Investigative Site
    Trois-Rivières, Quebec G9A 3X2, Canada
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Prague, 128 00, Czechia
  • Novartis Investigative Site
    Prague, 148 00, Czechia
  • Novartis Investigative Site
    Uherské Hradiště, 686 01, Czechia
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Esbjerg, 6700, Denmark
  • Novartis Investigative Site
    Vejle, DK-7100, Denmark
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tartu, 50708, Estonia
  • Novartis Investigative Site
    Helsinki, 00290, Finland
  • Novartis Investigative Site
    Kuopio, 70100, Finland
  • Novartis Investigative Site
    Lahti, 15850, Finland
  • Novartis Investigative Site
    Turku, 20520, Finland
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Marseille, 13008, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Dresden, 01067, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Pécs, Baranya 7623, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Cona, FE 44124, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Gjettum, 1346, Norway
  • Novartis Investigative Site
    Moss, 1538, Norway
  • Novartis Investigative Site
    Bydgoszcz, 85-168, Poland
  • Novartis Investigative Site
    Krakow, 30-002, Poland
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
  • Novartis Investigative Site
    Ponte de Lima, 4990-041, Portugal
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Badalona, Barcelona 08916, Spain
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Bilbao, Bizkaia 48013, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Malmö, 221 85, Sweden
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Novartis Investigative Site
    Sankt Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Pendik 34899, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Sihhiye-Altindag 06230, Turkey (Türkiye)

Showing the first 100 of 104 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Stone JH, Venhoff N, Buttgereit F, Dejaco C, Schmidt WA, Spiera R, Blanco R, Rubbert-Roth A, Von Frenckell C, Blockmans D, Terrier B, Tracey G, Hauge EM, Keyport MP, Ng J, Hiremath R, Fu R, Cho G, Bacher G, Thiel J, Mendelson MH. Secukinumab for Giant Cell Arteritis. NEJM Evid. 2026 Jul;5(7):EVIDoa2600112. doi: 10.1056/EVIDoa2600112. Epub 2026 Jun 3. PubMed 42234457 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2025, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2021
First posted
Jun 18, 2021
StartActual
Oct 6, 2021
Primary completionActual
Apr 11, 2025
CompletionActual
Feb 18, 2026
Results delay requested
Mar 27, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04930094
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Oct 6, 2021
Primary completion
Apr 11, 2025
Completion
Feb 18, 2026
Last update
Mar 31, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion